ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Warner Sells Rights To Leo For $1 Billion

by Ann M. Thayer
September 28, 2009 | APPEARED IN VOLUME 87, ISSUE 39

Warner Chilcott is selling U.S. rights to topical psoriasis treatments and other development-stage dermatology products it had licensed, as well as product inventories, back to Denmark’s Leo Pharma for $1 billion. The two companies have been partners since 2003. Warner Chilcott, with headquarters in Ireland, will continue to distribute the dermatology products until the end of the year. It will use the money from the sale to pay down debt and help finance its pending acquisition of Procter & Gamble’s pharmaceutical business (C&EN, Aug. 31, page 8). Earlier this month, Leo Pharma agreed to acquire the Australian specialty pharmaceutical firm Peplin for $288 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment